Geneva, 18 April 2023: This EASL Policy Statement about risk-based surveillance for hepatocellular carcinoma (HCC) among patients with cirrhosis demonstrates how risk-based surveillance has the potential to reduce not only deaths from HCC but also the costs of offering HCC surveillance.